Efficacy of nebivolol on flow-mediated dilation in patients with slow coronary flow

Basit Öğe Kaydı
dc.authorscopusid7003992013
dc.authorscopusid25121970100
dc.authorscopusid14030823200
dc.authorscopusid8615642100
dc.authorscopusid19337952100
dc.authorscopusid7007162316
dc.contributor.authorAlbayrak, Sinan
dc.contributor.authorOrdu, Serkan
dc.contributor.authorYuksel, Hatice
dc.contributor.authorOzhan, Hakan
dc.contributor.authorYazgan, Ömer
dc.contributor.authorYazici, Mehmet
dc.date.accessioned2024-09-25T19:44:13Z
dc.date.available2024-09-25T19:44:13Z
dc.date.issued2009
dc.departmentAbant İzzet Baysal Üniversitesien_US
dc.description.abstractSlow coronary flow (SCF) is the phenomenon of slow progression of angiographic contrast in the coronary arteries in the absence of stenosis in the epicardial vessels in some patients presenting with chest pain. There are no definite treatment modalities for patients with SCF. Our aim was to investigate the efficacy of nebivolol in patients with slow coronary flow by monitoring its effects on endothelial function and different markers of inflammation. Forty-two patients (16 females, 26 males; mean age, 55±10) with slow coronary flow (SCF) were included in the study. After baseline assessment, the patients were administered nebivolol 5 mg once daily. After 12 weeks of nebivolol therapy, the biochemical and ultrasonographic examinations were repeated. Chest pain relief was detected in 38 patients after treatment (90%). Systolic and diastolic blood pressure and high sensitive CRP were significantly decreased after nebivolol therapy. Among brachial artery dilation variables that reflect endothelial function, basal resistive index (RI), post-flow mediated dilation RI, and post-nitrate mediated dilation RI were significantly decreased after therapy. Nebivolol is effective at improving endothelial function in patients with SCF. It controls chest pain, decreases CRP, and has favorable effects on brachial artery dilation variables in patients with coronary slow flow.en_US
dc.identifier.doi10.1536/ihj.50.545
dc.identifier.endpage553en_US
dc.identifier.issn1349-3299
dc.identifier.issue5en_US
dc.identifier.pmid19809204en_US
dc.identifier.scopus2-s2.0-74849117353en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage545en_US
dc.identifier.urihttps://doi.org/10.1536/ihj.50.545
dc.identifier.urihttps://hdl.handle.net/20.500.12491/12724
dc.identifier.volume50en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.relation.ispartofInternational Heart Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmzYK_20240925en_US
dc.subjectCoronary slow flowen_US
dc.subjectNebivololen_US
dc.titleEfficacy of nebivolol on flow-mediated dilation in patients with slow coronary flowen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu